Deliver Your News to the World

Bristol-Myers Squibb Statement On Muraglitazar, An Investigational Oral Treatment For Type 2 Diabetes


PRINCETON, NEW JERSEY (December 22, 2005) -- As previously disclosed, Bristol-Myers Squibb Company (NYSE: BMY) agreed to begin discussions with Merck & Co., Inc. to terminate the collaborative agreement for muraglitazar, the company’s investigational oral medicine for the treatment of type 2 diabetes.

The companies have reached a mutually acceptable termination agreement, with all rights to muraglitazar returning to Bristol-Myers Squibb as of December 21, 2005. The termination agreement also covers the reversion to Bristol-Myers Squibb of a back-up compound to muraglitazar.

Bristol-Myers Squibb is continuing discussions with the U.S. Food and Drug Administration (FDA) and is considering a range of options including conducting additional studies or terminating further development of muraglitazar. The additional studies could take approximately five years to complete.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

This press release contains certain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995 regarding a product in development that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainty of the success of the research and development activities; decisions by regulatory authorities regarding whether and when to approve any new drug application for a product candidate that may result from the research, as well as their decisions regarding labeling and other matters that could affect the commercial potential of such product candidate; and competitive developments. A further list and description of risks and uncertainties can be found in the Bristol-Myers Squibb’s Annual Report on Form 10-K for the fiscal year ended December 31, 2004, and in its reports on Form 10-Q and Form 8-K. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.